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Simian virus 40 (SV40) is a monkey virus that was introduced in the human population by contaminated poliovaccines, produced in
SV40-infected monkey cells, between 1955 and 1963. Epidemiological evidence now suggests that SV40 may be contagiously transmitted in
humans by horizontal infection, independent of the earlier administration of SV40-contaminated poliovaccines. This evidence includes
detection of SV40 DNA sequences in human tissues and of SV40 antibodies in human sera, as well as rescue of infectious SV40 from a
human tumor. Detection of SV40 DNA sequences in blood and sperm and of SV40 virions in sewage points to the hematic, sexual, and
orofecal routes as means of virus transmission in humans. The site of latent infection in humans is not known, but the presence of SV40 in
urine suggests the kidney as a possible site of latency, as it occurs in the natural monkey host. SV40 in humans is associated with
inflammatory kidney diseases and with specific tumor types: mesothelioma, lymphoma, brain, and bone. These human tumors correspond to
the neoplasms that are induced by SV40 experimental inoculation in rodents and by generation of transgenic mice with the SV40 early region
gene directed by its own early promoter–enhancer. The mechanisms of SV40 tumorigenesis in humans are related to the properties of the
two viral oncoproteins, the large T antigen (Tag) and the small t antigen (tag). Tag acts mainly by blocking the functions of p53 and RB tumor
suppressor proteins, as well as by inducing chromosomal aberrations in the host cell. These chromosome alterations may hit genes important
in oncogenesis and generate genetic instability in tumor cells. The clastogenic activity of Tag, which fixes the chromosome damage in the
infected cells, may explain the low viral load in SV40-positive human tumors and the observation that Tag is expressed only in a fraction of
tumor cells. ‘‘Hit and run’’ seems the most plausible mechanism to support this situation. The small tag, like large Tag, displays several
functions, but its principal role in transformation is to bind the protein phosphatase PP2A. This leads to constitutive activation of the Wnt
pathway, resulting in continuous cell proliferation. The possibility that SV40 is implicated as a cofactor in the etiology of some human tumors
has stimulated the preparation of a vaccine against the large Tag. Such a vaccine may represent in the future a useful immunoprophylactic and
immunotherapeutic intervention against human tumors associated with SV40.
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The relationship of simian virus 40 (SV40) with the ature (Barbanti-Brodano et al., 1998; Butel and Lednicky,human species has focused on two main aspects: the
circulation of the virus in humans by contagious transmis-
sion and its association, as a possible etiologic cofactor, with
some human tumors. Contrasting reports have appeared on
both these subjects and several reviews have analyzed and
discussed the different contributions published in the liter-0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.09.004
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E-mail address: tgm@unife.it (M. Tognon).1999; Carroll-Pankhurst et al., 2001; Ferber, 2002a,b;
Geissler, 1990; Jasani et al., 2001; Klein et al., 2002;
Lednicky and Butel, 1999; Monini et al., 1995; Mortimer
et al., 1981; Pennisi, 1997; Rollison and Shah, 2002; Shah,
2000; Strickler and Goedert, 1998; Strickler and The Inter-
national SV40 Working Group, 2001; Strickler et al., 1996,
1998; Testa et al., 1998; Vilchez et al., 2003). As a
consequence of these conflicting results, a considerable
debate has developed in the scientific community. An
excellent analysis has recently addressed the problems
raised by this controversy, discussing and evaluating the
pertinent literature on SV40 infection of humans and on its
Minireview2involvement in human tumors (Garcea and Imperiale,
2003). More than examining again in detail all the existing
data, in the present review we consider the main results
supporting SV40 infection of humans and its association
with human tumors, and comment on the hypotheses arising
from these results.Epidemiology of SV40 infection in humans
Natural infection by SV40 in humans was considered a
rare event, restricted to people living in contact with
monkeys, the natural hosts of the virus, such as inhabitants
of Indian villages located close to the jungle, and persons
attending to monkeys in zoos and animal facilities (Shah and
Nathanson, 1976). This epidemiological evidence, however,
did not consider that massive infection of the human
population by SV40 occurred between 1955 and 1963,
when hundreds of millions of persons in the United States,
Canada, Europe, Asia and Africa were vaccinated with both
inactivated and live polio vaccines contaminated with in-
fectious SV40 (Carbone et al., 1997b). Soon it was shown
that people vaccinated with contaminated polio vaccines
shed infectious SV40 in stools for at least 5 weeks after
vaccination (Melnick and Stinebaugh, 1962). This observa-
tion suggested that SV40 could be transmitted by recipients
of contaminated polio vaccines to contacts by the orofecal
route, raising the possibility that, although human cells are
less susceptible to SV40 replication compared to monkey
cells (O’Neill and Carroll, 1981; Shein and Enders, 1962),
SV40 would spread in humans by horizontal infection.
This hypothesis is now supported by several observa-
tions, in agreement with the indications of a scientific panel
that recently established the importance of assessing the
ways of contagion by SV40 and the mechanisms of SV40
transmission in humans (Ferber, 2002b). First, SV40 DNA
sequences were detected in normal and neoplastic tissues of
persons too young (1 to 30 years) or too old (60 to 85 years)
to have been vaccinated with SV40-contaminated polio
vaccines (Barbanti-Brodano et al., 1998; Bergsagel et al.,
1992; Carbone et al., 1994, 1996; Lednicky et al., 1997;
Martini et al., 1996, 2002). This finding may also explain
the lack of difference in cancer incidence between individ-
uals vaccinated with SV40-contaminated and SV40-free
polio vaccines (Strickler and Goedert, 1998). Second,
SV40 sequences were detected in blood and sperm speci-
mens of neoplastic and normal individuals (David et al.,
2001; Li et al., 2002a,b; Martini et al., 1995, 1996, 1998,
2002; Yamamoto et al., 2000) and SV40 virions were found
in urine and sewage samples (Li et al., 2002b; Vastag,
2002), indicating that the hematic, sexual and orofecal
routes of transmission are likely to be responsible for
SV40 horizontal infection in humans. Third, infectious
SV40 was rescued by transfection of CV-1 monkey cells
with the DNA of an SV40-positive human choroid plexus
carcinoma (Lednicky et al., 1995). Finally, antibodies toSV40 capsid antigens were found in human sera. One study
reported the presence of SV40 antibodies in human sera
before the introduction of poliovirus vaccination (Geissler et
al., 1985), raising the possibility that SV40 or an SV40-like
virus was circulating in humans before the use of contam-
inated vaccines. This investigation, however, was conducted
before the discovery of the two ubiquitous human poly-
omaviruses BK (BKV) and JC (JCV) (Imperiale, 2000,
2001) which cross-react antigenically with SV40. Therefore,
the specificity of the antibodies detected in this study may
be questioned. The antigenic cross-reaction between the two
human polyomaviruses and SV40 has been so far the most
difficult problem to study the real diffusion of SV40
infection in humans. The tests used in serological surveys
were a plaque reduction assay and an ELISA test based
either on SV40 virions or on the SV40 recombinant VP1
capsid protein produced in a baculovirus system. By these
assays, a limited number (1.3% to 15.6%) of normal human
sera showed antibodies to SV40 (Basetse et al., 2002; Butel
et al., 1999, 2003; De Sanjose et al., 2003; Jafar et al., 1998;
Rollison et al., 2003; Shah, 1966; Shah et al., 1971; Viscidi
et al., 2003), suggesting a low virus circulation in the human
population. All these serological tests, however, do not
exclude cross-reaction with BKV and JCV capsid proteins.
Preliminary analyses in our laboratory indicate that SV40-
specific antibodies could be present in a fraction of the
human population larger than previously reported. On the
whole, these observations support the notion that infectious
SV40 is present in human tissues and may be contagiously
transmitted in the human population either directly by
person-to-person contacts or indirectly by the orofecal route,
independently from the earlier administration of SV40-
contaminated polio vaccines.Evidence for the association of SV40 with human
diseases
SV40 sequences were detected in kidney and cells of
urine sediments from patients with focal segmental glomer-
ulosclerosis and SV40 was isolated by cocultivation of cells
from urine sediments of such patients with CV-1 monkey
cells (Li et al., 2002b). Several strains of SV40 were rescued
in this study, including strain 776 and other strains bearing
mutations in the early and late regions. In addition, SV40
sequences were detected, in association with BKV sequen-
ces, in kidneys of patients with post-transplantation inter-
stitial nephritis (Li et al., 2002a). Since the two SV40-like
human polyomaviruses BK and JC are implicated in human
nephropathy in renal allograft recipients (Baksh et al., 2001;
Drachenberg et al., 1999; Hogan et al., 1980; Howell et al.,
1999; Nickeleit et al., 1999, 2000a,b; Randhawa et al.,
1999), these results suggest that SV40 too may be etiolog-
ically related to these two syndromes and may cooperate, by
co-infection with BKV, to the etiopathogenesis of chronic
interstitial nephritis (Li et al., 2002a). In addition, the
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as a site of virus latency, like in the natural monkey host
(Sweet and Hilleman, 1960).
In spite of its possible involvement in these inflammatory
diseases, the main role postulated for SV40 in human
pathology derives from its association with some human
cancers: mesothelioma, lymphoma, brain and bone tumors
as well as thyroid, pituitary and parotid gland tumors
(Bergsagel et al., 1992; Carbone et al., 1994, 1996; Cris-
taudo et al., 1995; Galateau-Salle et al., 1998; Geissler,
1990; Griffiths et al., 1998; Huang et al., 1999; Jasani et al.,
2001; Klein et al., 2002; Lednicky et al., 1997; Martinelli et
al., 2002; Martini et al., 1996, 1998, 2002; Mendoza et al.,
1998; Monini et al., 1995; Pacini et al., 1998; Pepper et al.,
1996; Rizzo et al., 2001; Shivapurkar et al., 2002; Strickler
et al., 1996; Suzuki et al., 1997; Testa et al., 1998; Vivaldi et
al., 2003; Vilchez et al., 2002; Woloschak et al., 1995).
These human tumors correspond to the neoplasms that are
induced by SV40 experimental inoculation in rodents (Bar-
banti-Brodano et al., 1998) or by generation of transgenic
mice with the SV40 early region gene directed by its own
early promoter–enhancer (Brinster et al., 1984; Palmiter et
al., 1985; Van Dyke et al., 1987). It is notable that mice
transgenic for the SV40 Tag gene directed by the JCV
regulatory region develop choroid plexus carcinomas (Fei-
genbaum et al., 1992) like mice transgenic for the SV40 Tag
gene controlled by its own natural promoter, indicating that
polyomavirus transforming sequences per se play a critical
role, independently from the control region that directs their
expression, in the determination of tissue targeting and
pathogenicity. The association of SV40 with human tumors
is proved by the presence of SV40 sequences in tumor
tissues and by the expression of the virus-specific RNA and
proteins. The SV40 sequences were generally detected in an
episomal state and rarely integrated in tumor DNA (Men-
doza et al., 1998; Pacini et al., 1998). In addition, infectious
SV40 was isolated from a choroid plexus carcinoma (Ledn-
icky et al., 1995). Human brain tumors, like kidneys
affected by post-transplantation nephritis (Li et al., 2002a),
are often co-infected by SV40 and BKV (Martini et al.,
1996), suggesting a possible co-operation between the two
polyomaviruses in the oncogenic effect or a helper function
of BKV for SV40 replication in human cells. Negative
results were also reported on the association of SV40 with
human tumors (Capello et al., 2003; De Sanjose et al.,
2003; Engels et al., 2002; Gordon et al., 2002; Shah, 2000;
Strickler and The International SV40 Working Group,
2001; Volter et al., 1997). However, Capello et al. (2003),
while failing to detect SV40 sequences in lymphomas,
reproducibly found them in mesotheliomas, and Volter et
al. (1997) investigated human tumor samples for the pres-
ence of SV40 late gene sequences which are unlikely to be
involved in the process of SV40-induced transformation
and tumorigenesis. The contribution by Engels et al. (2002)
raised a controversy because the assay used in this study
was estimated to be affected by low sensitivity (Carbone etal., 2003; Engels et al., 2003). To settle the dispute among
different results on SV40 in human tumors, two multi-
institutional studies were performed to examine the pres-
ence of SV40 in human malignant mesotheliomas (Strickler
and The International SV40 Working Group, 2001; Testa et
al., 1998). Unfortunately, the two investigations reached
opposite conclusions, leaving the question unresolved. Re-
cently, a serological survey for antibodies to capsid proteins
of BKV, JCVand SV40 indicated no association of the three
viruses with human astrocytic brain tumors (Rollison et al.,
2003). Search for antibodies to polyomavirus structural
proteins (De Sanjose et al., 2003; Rollison et al., 2003)
may not be the best assay to evaluate polyomavirus associ-
ation with human tumors. Indeed, antibodies to polyomavi-
rus large T and small t oncoproteins may better reflect
immunization against polyomavirus tumor-specific antigens.
Transformation of rodent and human cells by SV40 is
induced by the two oncoproteins encoded in the early
region of the viral genome, the large tumor antigen (Tag)
(Simmons, 2000) and the small tumor antigen (tag) (Run-
dell and Parakati, 2001). Both these proteins display
multiple functions. However, the main activity of Tag for
cell transformation and tumorigenesis is to target key
cellular proteins, such as the tumor suppressor p53 and
pRB family proteins, inactivating their functions (Pipas and
Levine, 2001; Sa´enz-Robles et al., 2001). The principal role
of tag in transformation is to bind the serine–threonine
protein phosphatase PP2A (Beck et al., 1998; Pallas et al.,
1990). This interaction leads to inhibition of PP2A with
consequent constitutive activation of the Wnt pathway
(Cadigan and Nusse, 1997), lack of inactivation of h-
catenin, its translocation to the nucleus and stimulation of
cell proliferation (Ikeda et al., 2000; Willert and Nusse,
1998). The block of PP2A functions by tag induces an
alteration of the actin cytoskeleton and tight junctions,
resulting in loss of cell polarity and tumor invasiveness
(Nunbhakdi-Craig et al., 2003). Small tag interacts with the
centrosome and blocks mitosis in human cells (Gaillard et
al., 2001), suggesting that it may disrupt cell cycle pro-
gression. Recently, it was shown that tag activates, in
human mammary epithelial cells, phosphatidylinositol 3-
kinase (Zhao et al., 2003), an enzyme involved in pathways
crucial for cell proliferation and transformation. The func-
tions of SV40 Tag must be continuously expressed in
SV40-transformed cells to establish and maintain transfor-
mation, since rodent and human cells transformed by
temperature-sensitive mutants of Tag lose the transformed
phenotype at the non-permissive temperature (Brugge and
Butel, 1975; Martin and Chou, 1975; Osborn and Weber,
1975; Tegtmeyer, 1975).
This condition is in contrast with the evidence that the
viral load in SV40-positive human tumors is generally low
(less than one genome equivalent per cell) and Tag is
expressed only in a fraction of tumor cells (Barbanti-
Brodano et al., 1998; Garcea and Imperiale, 2003; Martini
et al., 1998). The situation, however, may be more complex
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chromosome aberrations (Ray et al., 1990; Stewart and
Bacchetti, 1991) which likely affect the functions of genes
involved in tumorigenesis, such as oncogenes, tumor sup-
pressor and DNA repair genes (Coleman and Tsongalis,
2002; Reinartz, 2002; Shimamoto and Ohyashiki, 2002).
Once chromosomal damage has been triggered in tumors
and chromosomal aberrations have reached a threshold,
genomic instability ensues (Lengauer et al., 1998), due to
the functional alteration of DNA repair genes, leading to
more genetic lesions and tumor progression (Coleman and
Tsongalis, 2002; Lengauer et al., 1998; Shimamoto and
Ohyashiki, 2002). This process does not need the mainte-
nance of the original injury that initiated tumorigenesis. The
same course of events may occur in SV40-positive human
tumors, where the clastogenic activity of Tag, like a chem-
ical or physical carcinogen, initiates the tumorigenic process
by hitting the cell genome, then becomes dispensable and is
lost in the progression phase of the tumor, when the
accumulation of genetic alterations renders the presence of
viral transforming functions unnecessary. Immunoselection
may even be exerted against persistently SV40-infected
cells, while genetically mutated, uninfected cells may have
a proliferative advantage and become the prevalent popula-
tion in the tumor. This ‘‘hit and run’’ mechanism was
originally proposed to explain transformation of human
cells by the mutagenic herpesviruses (Galloway and
McDougall, 1983; Schlehofer and zur Hausen, 1982), and
has been recently suggested to be operative in colorectal
carcinogenesis associated with JCV (Ricciardiello et al.,
2003). Contrary to SV40-transformed human cells, in trans-
formed rodent cells, where SV40 Tag is equally clastogenic,
SV40 sequences are not lost during chromosomal rearrange-
ments. This difference may depend on the fact that rodent
cells are non-permissive to SV40 replication and therefore
the incoming viral DNA is integrated and fixed into the cell
genome (Barbanti-Brodano et al., 1998). Because human
cells are semi-permissive to virus replication, most of the
SV40 DNA molecules remain in an episomal state, even
when cell transformation is established (Barbanti-Brodano
et al., 1998), rendering them more prone to be lost.
Another observation explaining the low viral load in
SV40-positive human tumors is that SV40 Tag induces a
paracrine mechanism by which a growth factor, such as
insulin-like growth factor type I (IGF-I), is secreted by
SV40-positive cells (Porcu et al., 1992) and may stimulate
proliferation of surrounding cells that do not contain SV40.
More recently, it was shown that Tag activates in mesothe-
lial cells an autocrine–paracrine loop, involving the hepa-
tocyte growth factor (HGF) and its cellular receptor, the
oncogene c-met (Cacciotti et al., 2001), as well as the
vascular endothelial growth factor (VEGF) and its cellular
receptor (Cacciotti et al., 2002; Catalano et al., 2002). HGF
and VEGF, released from SV40-positive cells, bind their
receptors in neighboring and distant SV40-positive and
SV40-negative cells, driving them into proliferation andtumorigenesis. Thus, not every cell would need to express
polyomavirus Tag in order to participate in tumor growth.
The role of SV40 Tag in the pathogenesis of human
mesothelioma was shown by: (i) its ability to bind in vivo
p53 and RB family proteins in human mesothelioma sam-
ples (Carbone et al., 1997a; De Luca et al., 1997); (ii)
activation of Notch-1, a gene promoting cell cycle progres-
sion and cell proliferation, in primary human mesothelial
cells (Bocchetta et al., 2003); (iii) induction of apoptosis in
mesothelioma cells transfected with antisense DNA to the
SV40 early region gene (Waheed et al., 1999); (iv) the
presence of SV40 Tag specific antibodies in sera of meso-
thelioma patients (Bright et al., 2002); and (v) the poorer
prognosis of mesotheliomas harboring SV40 early region
sequences compared to SV40-negative mesotheliomas (Pro-
copio et al., 2000). Moreover, mesothelial cells are partic-
ularly susceptible to infection and transformation by SV40
(Bocchetta et al., 2000; Cacciotti et al., 2001). Asbestos,
which is the main cause of human mesothelioma, cooperates
with SV40 in transformation of murine cells as well as of
human fibroblasts and mesothelial cells (Bocchetta et al.,
2000; Dubes, 1993), suggesting that SV40 and asbestos
may be co-carcinogens in the pathogenesis of mesotheli-
oma. Fluorescent in situ hybridization analysis indicated
that the RB and cyclin E/CDK2 genes undergo the same
type of deregulation during the cell cycle in asbestos-
treated and SV40-transformed human mesothelial cells as
well as in mesothelioma cells (Dopp et al., 2002).
Recently, it was shown that SV40 tumor antigens induce
telomerase activity in human mesothelial cells, but not in
human fibroblasts (Foddis et al., 2002), suggesting that
both SV40 oncoproteins specifically participate in the
immortalization of mesothelial cells during mesothelioma
development.
The SV40 sequences detected in Italian samples (Bar-
banti-Brodano et al., 1998; Carbone et al., 1996; Cristaudo
et al., 1995; Martini et al., 1998; Pacini et al., 1998; Tognon
et al., 2001) constantly showed two 72-bp repeats in the
enhancer domain of the regulatory region. Duplication of
the 72-bp regulatory sequence gives a growth advantage to
SV40 for replication in permissive cells in culture (Butel
and Lednicky, 1999). The SV40 strains which contaminated
polio vaccines show a regulatory region which contains
either one or two 72-bp repeats (Rizzo et al., 1999). SV40
strains with two 72-bp repeats detected in human tissues
may therefore represent viruses circulating in the human
population after poliovirus vaccination. As pointed out in a
recent critical review (Vilchez et al., 2003), descriptive
epidemiological surveys are unable to distinguish between
exposure to and infection by SV40. Thus, the SV40 strains
with two 72-bp repeats in the regulatory region, present as
contaminants in poliovirus vaccines, may have a selective
advantage for infection and replication in human cells and
propagate more easily in humans. SV40 strain variability,
found in the United States (Lednicky and Butel, 2001;
Vilchez et al., 2003), could be due to the heterogeneous
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type strain 776, which has two 72-bp repeats in the enhancer
domain of the regulatory region, was the main representa-
tive among the different SV40 strains detected in kidney,
urine and blood samples of an American group consisting of
normal persons and patients affected by focal segmental
glomerulosclerosis (Li et al., 2002b). SV40 regulatory
region sequences with two 72-bp repeats were detected in
the United States also in human osteosarcomas and meso-
theliomas (Lednicky et al., 1997; Pass et al., 1998) as well
as in monkey tissues (Lednicky et al., 1998; Stewart et al.,
1998). The SV40 strain homogeneity detected by different
groups in Italian patients may reflect the more homogeneous
population present in Italy. Indeed, JCV, which is closely
related to SV40, has a geographical strain distribution
(Agostini et al., 1997; Barbanti-Brodano et al., 1998).
The problems of the SV40 infection in human population
and of SV40 contribution to human cancer may be summa-
rized by considering a recent evaluation by the Immuniza-
tion Safety Review Committee established by the Institute
of Medicine of the National Academies (Stratton et al.,
2002). The Committee stated that ‘‘the evidence is inade-
quate to accept or reject a causal relationship between
SV40-containing polio vaccines and cancer’’. In fact, the
epidemiological studies conducted in the past are flawed by
the difficulty to establish which individuals received con-
taminated vaccines, to determine the dosage of infections
SV40 present in different lots of vaccine (due to formalin
inactivation of poliovirus which may have variably affected
SV40 infectivity), and finally to follow large cohorts of
subjects for several decades after virus exposure to monitor
for cancer development (Vilchez et al., 2003). The Com-
mittee concluded that ‘‘the biological evidence is strong that
SV40 is a transforming virus, but it is of moderate strength
that SV40 exposure from polio vaccine is related to SV40
infection in humans and that SV40 exposure could lead to
cancer in humans under natural conditions’’. The Commit-
tee also recommended development of specific and sensitive
serologic tests for SV40 and use of standardized techniques
that should be accepted and shared by all laboratories
involved in SV40 detection.
Although it may seem somehow a premature effort, the
conviction that SV40 is implicated as a cofactor in the
etiology of some human tumors has prompted programs to
prepare a vaccine against the main viral oncoprotein, the
SV40 Tag (Imperiale et al., 2001). A recombinant vaccinia
vector containing a safety-modified SV40 Tag sequence was
constructed (Xie et al., 1999). Such modified Tag excludes
the p53 and RB protein binding sites as well as the amino-
terminal oncogenic CRI and J domains (Sa´enz-Robles et al.,
2001), but preserves the immunogenic regions. Tumorigen-
esis studies carried out in vivo indicated that this vector can
efficiently prime the immune response to provide effective,
antigen-specific prophylactic and therapeutic protection
against SV40 Tag-expressing lethal tumors (Xie et al.,
1999). Although truncation of Tag at the carboxyl terminus,where the p53 binding sites are located, yields unstable
products (Sa´enz-Robles et al., 2001), such types of vaccines
may represent in the future a useful immunoprophylactic
and immunotherapeutic intervention against human tumors
associated with SV40.Acknowledgments
The work of the authors reported in this article was
supported by funds from Associazione Italiana per la
Ricerca sul Cancro (AIRC) to G.B.B. and M.T., from
MIUR local funds to G.B.B., M.T. and A.C. and from
MIUR COFIN funds to M.T. We thank Annalisa Peverati
and Augusto Bevilacqua for excellent assistance in prepar-
ing the manuscript.References
Agostini, H.T., Yanagihara, R., Davis, V., Ryschkewitsch, C.F., Stoner,
G.L., 1997. Asian genotypes of JC virus in Native Americans and in
a Pacific Island population: markers of viral evolution and human mi-
gration. Proc. Natl. Acad. Sci. U. S. A. 94, 14542–14546.
Baksh, F.K., Finkelstein, S.D., Swalsky, P.A., Stoner, G.L., Ryschkewitsch,
C.F., Randhawa, P., 2001. Molecular genotyping of BK and JC viruses in
human polyomavirus-associated interstitial nephritis after renal trans-
plantation. Am. J. Kidney Dis. 38, 354–365.
Barbanti-Brodano, G., Martini, F., De Mattei, M., Lazzarin, L., Corallini,
A., Tognon, M., 1998. BK and JC human polyomaviruses and simian
virus 40: natural history of infection in humans, experimental oncoge-
nicity, and association with human tumors. Adv. Virus Res. 50, 69–99.
Basetse, H.R., Lecatsas, G., Gerber, L.J., 2002. An investigation of the
occurrence of SV40 antibodies in South Africa. S. Afr. Med. J. 92,
825–828.
Beck Jr., G.R., Zerler, B.R., Moran, E., 1998. Introduction to DNA
tumor viruses: adenovirus, simian virus 40, and polyomavirus. In:
McCance, D.J. (Ed.), Human Tumor Viruses. ASM Press, Washing-
ton, DC, pp. 51–86.
Bergsagel, D.J., Finegold, M.J., Butel, J.S., Kupsky, W.J., Garcea, R.L.,
1992. DNA sequences similar to those of simian virus SV40 in epen-
dymomas and choroid plexus tumors of childhood. N. Engl. J. Med.
326, 988–993.
Bocchetta, M., Di Resta, I., Powers, A., Fresco, R., Tosolini, A., Testa, J.R.,
Pass, H.I., Rizzo, P., Carbone, M., 2000. Human mesothelial cells are
unusually susceptible to SV40 mediated transformation and asbestos
co-carcinogenicity. Proc. Natl. Acad. Sci. U. S. A. 97, 10214–10219.
Bocchetta, M., Miele, L., Pass, H.I., Carbone, M., 2003. Notch-1 induction,
a novel activity of SV40 required for growth of SV40-transformed
human mesothelial cells. Oncogene 22, 81–89.
Bright, R.K., Kimchl, E.T., Shearer, M.H., Kennedy, R.C., Pass, H.I., 2002.
SV40 Tag-specific cytotoxic T lymphocytes generated from the periph-
eral blood of malignant pleural mesothelioma patients. Cancer Immu-
nol. Immunother. 50, 682–690.
Brinster, R.L., Chen, H.Y., Messing, A., Van Dyke, T., Levine, A.J., Pal-
miter, R.D., 1984. Transgenic mice harboring SV40 T-antigen genes
develop characteristic brain tumors. Cell 37, 367–379.
Brugge, J.S., Butel, J.S., 1975. Role of simian virus 40 gene A function in
maintenance of transformation. J. Virol. 15, 619–635.
Butel, J.S., Lednicky, J.A., 1999. Cell and molecular biology of simian
virus 40: implications for human infections and disease. J. Natl. Cancer
Inst. 91, 119–134.
Butel, J.S., Jafar, S., Wong, C., Arrington, A.S., Opekun, A.R., Finegold,
Minireview6M.J., Adam, E., 1999. Evidence of SV40 infections in hospitalized
children. Hum. Pathol. 30, 1496–1502.
Butel, J.S., Wong, C., Vilchez, R.A., Szucs, G., Domok, I., Kriz, B., Slonim,
D., Adam, E., 2003. Detection of antibodies to polyomavirus SV40 in
two central European countries. Cent. Eur. J. Publ. Health 11, 3–8.
Cacciotti, P., Libener, R., Betta, P., Martini, F., Porta, C., Procopio, A.,
Strizzi, L., Penengo, L., Tognon, M., Mutti, L., Gaudino, G., 2001.
SV40 replication in human mesothelial cells induces HGF/Met receptor
activation: a model for viral-related carcinogenesis of human malignant
mesothelioma. Proc. Natl. Acad. Sci. U. S. A. 98, 12032–12037.
Cacciotti, P., Strizzi, L., Vianale, G., Iaccheri, L., Libener, R., Porta, C.,
Tognon, M., Gaudino, G., Mutti, L., 2002. The presence of simian virus
40 sequences in mesothelioma and mesothelial cells is associated with
high levels of vascular endothelial growth factor. Am. J. Respir. Cell
Mol. Biol. 26, 189–193.
Cadigan, K.M., Nusse, R., 1997. Wnt signaling: a common theme in ani-
mal development. Genes Dev. 11, 3286–3305.
Capello, D., Rossi, D., Gaudino, G., Carbone, A., Gaidano, G., 2003.
Simian virus 40 infection in lymphoproliferative disorders. Lancet
361, 88–89.
Carbone, M., Pass, H.I., Rizzo, P., Marinetti, M.R., Di Muzio, M., Mew,
D.J.Y., Levine, A.S., Procopio, A., 1994. Simian virus 40-like DNA
sequences in human pleural mesothelioma. Oncogene 9, 1781–1790.
Carbone, M., Rizzo, P., Procopio, A., Giuliano, M., Pass, H.I., Gebhardt,
M.C., Mangham, C., Hansen, M., Malkin, D.F., Bushart, G., Pompetti,
P., Picci, P., Levine, A.S., Bergsagel, J.D., Garcea, R.L., 1996. SV40-
like sequences in human bone tumors. Oncogene 13, 527–535.
Carbone, M., Rizzo, P., Grimley, P.M., Procopio, A., Mew, D.J.Y., Shridar,
V., de Bartolomeis, A., Esposito, V., Giuliano, M.T., Steinberg, S.M.,
Levine, A.S., Giordano, A., Pass, H.I., 1997a. Simian virus-40 large T-
antigen binds p53 in human mesotheliomas. Nat. Med. 3, 908–912.
Carbone, M., Rizzo, P., Pass, H.I., 1997b. Simian virus 40, poliovaccines
and human tumors: a review of recent developments. Oncogene 15,
1877–1888.
Carbone, M., Bocchetta, M., Cristaudo, A., Emri, S., Gazdar, A., Jasani, B.,
Lednicky, J., Miele, L., Mutti, L., Pass, H.J., Ramel, M., Rizzo, P.,
Testa, J.R., 2003. SV40 and human brain tumors. Int. J. Cancer 106,
140–142.
Carroll-Pankhurst, C., Engels, E.A., Strickler, H.D., Goedert, J.J., Wagner,
J., Mortimer Jr., E.A., 2001. Thirty-five year mortality following receipt
of SV40-contaminated polio vaccine during the neonatal period. Br. J.
Cancer 85, 1295–1297.
Catalano, A., Romano, M., Martinotti, S., Procopio, A., 2002. Enhanced
expression of vascular endothelial growth factor (VEGF) plays a critical
role in the tumor progression potential induced by simian virus 40 large
T antigen. Oncogene 21, 2896–2900.
Coleman, W.B., Tsongalis, G.J., 2002. The role of genomic instability in
the development of human cancer. In: Coleman, W.B., Tsongalis, G.J.
(Eds.), The Molecular Basis of Human Cancer. Humana Press, Totowa,
NJ, pp. 115–142.
Cristaudo, A., Vivaldi, A., Sensales, G., Guglielmi, G., Ciancia, E., Elisei,
R., Ottenga, F., 1995. Molecular biology studies on mesothelioma tu-
mor samples: preliminary data on H-ras, p21, and SV40. J. Environ.
Pathol. Toxicol. Oncol. 14, 29–34.
David, H., Mendoza, S., Konishi, T., Miller, C.W., 2001. Simian virus 40
is present in human lymphomas and normal blood. Cancer Lett. 162,
57–64.
De Luca, A., Baldi, A., Esposito, V., Howard, C.M., Bagella, L., Rizzo, P.,
Caputi, M., Pass, H.I., Giordano, G.G., Baldi, F., Carbone, M., Gior-
dano, A., 1997. The retinoblastoma gene family pRb/p105, p107,
pRb2/p130 and simian virus-40 large T-antigen in humanmesotheliomas.
Nat. Med. 3, 913–916.
De Sanjose, S., Shah, K.V., Domingo-Domenech, E., Engels, E.A., Fernan-
dez de Sevilla, A.F., Alvaro, T., Garcia-Villanueva, M., Romagosa, V.,
Gonzalez-Barca, E., Viscidi, R.P., 2003. Lack of serological evidence for
an association between simian virus 40 and lymphoma. Int. J. Cancer
104, 522–524.Dopp, E., Poser, I., Papp, T., 2002. Interphase FISH analysis of cell cycle
genes in asbestos-treated human mesothelial cells (HMC), SV40-trans-
formed HMC (MET-5A) and mesothelioma cells (COLO). Cell. Mol.
Biol. 48, 271–277.
Drachenberg, C.B., Beskow, C.O., Cangro, C.B., Bourquin, P.M., Simsir,
A., Fink, J., Weir, M., Klassen, D.K., Bartlett, S.T., Papadimitriou,
J.C., 1999. Human polyoma virus in renal allograft biopsies: morpho-
logical findings and correlation with urine cytology. Hum. Pathol. 30,
970–977.
Dubes, G.R., 1993. Asbestos mediates viral DNA transformation of
mouse cells to produce multilayered foci. Proc. Am. Assoc. Cancer
Res. 34, 185.
Engels, E.A., Sarkar, C., Daniel, R.W., Gravitt, P.E., Verma, K., Quezado,
M., Shah, K.V., 2002. Absence of simian virus 40 in human brain
tumors from Northern India. Int. J. Cancer 101, 348–352.
Engels, E.A., Gravitt, P.E., Daniel, R.W., Quezado, M., Shah, K.V.,
2003. Absence of simian virus 40 in human brain tumors from
Northern India; response to letter from Carbone et al. Int. J. Cancer
106, 143–145.
Feigenbaum, L., Hinrichs, S.H., Jay, G., 1992. JC virus and simian virus 40
enhancers and transforming proteins: role in determining tissue specif-
icity and pathogenicity in transgenic mice. J. Virol. 66, 1176–1182.
Ferber, D., 2002a. Monkey virus link to cancer grows stronger. Science
296, 1012–1015.
Ferber, D., 2002b. Creeping consensus on SV40 and polio vaccine. Science
298, 725–727.
Foddis, R., De Rienzo, A., Broccoli, D., Bocchetta, M., Stekala, E., Rizzo,
P., Tosolini, A., Grobelny, J.V., Jhanwar, S.C., Pass, H.I., Testa, J.R.,
Carbone, M., 2002. SV40 infection induces telomerase activity in hu-
man mesothelial cells. Oncogene 21, 1434–1442.
Gaillard, S., Fahrbach, K.M., Parkati, R., Rundell, K., 2001. Overexpres-
sion of simian virus 40 small-t antigen blocks centrosome function and
mitotic progression in human fibroblasts. J. Virol. 75, 9799–9807.
Galateau-Salle, F., Bidet, P., Iwatsubo, Y., Gennetay, E., Renier, A., Le-
tourneux, M., Patron, J.C., Moritz, S., Brochard, P., Jaurand, M.C.,
Freymuth, F., 1998. SV40-like DNA sequences in pleural mesothelio-
ma, bronchopulmonary carcinoma, and non-malignant pulmonary dis-
eases. J. Pathol. 184, 252–257.
Galloway, D.A., McDougall, J.K., 1983. The oncogenic potential of herpes
simplex viruses: evidence for a ‘hit and run’ mechanism. Nature 302,
21–24.
Garcea, R.L., Imperiale, M.J., 2003. Simian virus 40 infection of humans.
J. Virol. 77, 5039–5045.
Geissler, E., 1990. SV40 and human brain tumors. Prog. Med. Virol. 37,
211–222.
Geissler, E., Konzer, P., Scherneck, S., Zimmerman, W., 1985. Sera col-
lected before introduction of contaminated polio vaccine contain anti-
bodies against SV40. Acta Virol. 29, 420–423.
Gordon, G.J., Chen, C.J., Jaklitsch, M.T., Richards, W.G., Sugarbaker, D.J.,
Bueno, R., 2002. Detection and quantification of SV40 large T-anti-
gen DNA in mesothelioma tissues and cell lines. Oncol. Rep. 9,
631–634.
Griffiths, D.J., Nicholson, A.G., Weiss, R.A., 1998. Detection of SV40
sequences in human mesothelioma. Dev. Biol. Stand. 94, 127–136.
Hogan, T.F., Padgett, B.L., Walker, D.L., Borden, E.C., McBain, J.A.,
1980. Rapid detection and identification of JC virus and BK virus in
human urine by using immunofluorescence microscopy. J. Clin. Micro-
biol. 11, 178–183.
Howell, D.N., Smith, S.R., Butterly, D.W., Klassen, P.S., Krigman, H.R.,
Burchette Jr., J.L., Miller, S.E., 1999. Diagnosis and management of
BK polyomavirus interstitial nephritis in renal transplant recipients.
Transplantation 68, 1279–1288.
Huang, H., Reis, R., Yonekawa, Y., Lopes, J.M., Kleihues, P., Ohgaki, H.,
1999. Identification in human brain tumors of DNA sequences specific
for SV40 large T antigen. Brain Pathol. 9, 33–42.
Ikeda, S., Kishida, M., Matsuura, Y., Usui, H., Kikuchi, A., 2000. GSK-3h-
dependent phosphorylation of adenomatous polyposis coli gene product
Minireview 7can be modulated by h-catenin and protein phosphatase 2A complexed
with Axin. Oncogene 19, 537–545.
Imperiale, M.J., 2000. The human polyomaviruses, BKV and JCV: molec-
ular pathogenesis of acute disease and potential role in cancer. Virology
267, 1–7.
Imperiale, M.J., 2001. Oncogenic transformation by the human polyoma-
viruses. Oncogene 20, 7917–7923.
Imperiale, M.J., Pass, H.J., Sanda, M.J., 2001. Prospects for an SV40
vaccine. Semin. Cancer Biol. 11, 81–85.
Jafar, S., Rodriguez-Barradas, M., Graham, D.Y., Butel, J.S., 1998. Sero-
logical evidence of SV40 infections in HIV-infected and HIV-negative
adults. J. Med. Virol. 54, 276–284.
Jasani, B., Cristaudo, A., Emri, S.A., Gazdar, A.F., Gibbs, A., Krynska, B.,
Miller, C., Mutti, L., Radu, C., Tognon, M., Procopio, A., 2001. Asso-
ciation of SV40 with human tumours. Semin. Cancer Biol. 11, 49–61.
Klein, G., Powers, A., Croce, C.M., 2002. Association of SV40 with hu-
man tumors. Oncogene 21, 1141–1149.
Lednicky, J.A., Butel, J.S., 1999. Polyomaviruses and human tumors: a
brief review of current concepts and interpretations. Front. Biosci. 4,
153–164.
Lednicky, J.A., Butel, J.S., 2001. Simian virus 40 regulatory region struc-
tural diversity and the association of viral archetypal regulatory regions
with human brain tumors. Semin. Cancer Biol. 11, 39–47.
Lednicky, J.A., Garcea, R.L., Bergsagel, D.J., Butel, J.S., 1995. Natural
simian virus 40 strains are present in human choroid plexus and epen-
dymoma tumors. Virology 212, 710–717.
Lednicky, J.A., Stewart, A.R., Jenkins, J.J., III, Finegold, M.J., Butel, J.S.,
1997. SV40 DNA in human osteosarcomas shows sequence variation
among T-antigen genes. Int. J. Cancer 72, 791–800.
Lednicky, J.A., Arrington, A.S., Stewart, A.R., Dai, X.M., Wong, C., Jafar,
S., Murphey-Corb, M., Butel, J.S., 1998. Natural isolates of simian
virus 40 from immunocompromised monkeys display extensive genetic
heterogeneity: new implications for polyomavirus disease. J. Virol. 72,
3980–3990.
Lengauer, C., Kinzler, K.W., Vogelstein, B., 1998. Genetic instabilities in
human cancers. Nature 396, 643–649.
Li, R.M., Mannon, R.B., Kleiner, D., Tsokos, M., Bynum, M., Kirk, A.D.,
Kopp, J.B., 2002a. BK virus and SV40 co-infection in polyomavirus
nephropathy. Transplantation 74, 1497–1504.
Li, R.M., Tanawattanacharoen, S., Falk, R.A., Jennette, J.C., Kopp, J.B.,
2002b. Molecular identification of SV40 infection in human subjects
and possible association with kidney disease. J. Am. Soc. Nephrol. 13,
2320–2330.
Martin, R.G., Chou, J.Y., 1975. Simian virus 40 functions required for the
establishment and maintenance of malignant transformation. J. Virol.
15, 599–612.
Martinelli, M., Martini, F., Rinaldi, E., Caramanico, L., Magri, E., Grandi,
E., Carinci, F., Pastore, A., Tognon, M., 2002. Simian virus 40 se-
quences and expression of the viral large T antigen oncoprotein in
human pleomorphic adenomas of parotid glands. Am. J. Pathol. 161,
1127–1133.
Martini, F., De Mattei, M., Iaccheri, L., Lazzarin, L., Barbanti-Brodano, G.,
Tognon, M., Gerosa, M., 1995. Human brain tumors and simian virus
40. J. Natl. Cancer. Inst. 87, 1331.
Martini, F., Iaccheri, L., Lazzarin, L., Carinci, P., Corallini, A., Gerosa, M.,
Iuzzolino, P., Barbanti-Brodano, G., Tognon, M., 1996. SV40 early
region and large T antigen in human brain tumors, peripheral blood
cells, and sperm fluids from healthy individuals. Cancer Res. 56,
4820–4825.
Martini, F., Dolcetti, R., Gloghini, A., Iaccheri, L., Carbone, A., Boiocchi,
M., Tognon, M., 1998. Simian virus 40 footprints in human lympho-
proliferative disorders of HIV and HIV+ patients. Int. J. Cancer 78,
669–674.
Martini, F., Lazzarin, L., Iaccheri, L., Vignocchi, B., Finocchiaro, G.,
Magnani, I., Serra, M., Scotlandi, K., Barbanti-Brodano, G., Tognon,
M., 2002. Different simian virus 40 genomic regions and sequences
homologous with SV40 large T antigen in DNA of human brain andbone tumors and of leukocytes from blood donors. Cancer 94,
1037–1048.
Melnick, J.L., Stinebaugh, S., 1962. Excretion of vacuolating SV-40 virus
(papova virus group) after ingestion as a contaminant of oral polio-
vaccine. Proc. Soc. Exp. Biol. Med. 109, 965–968.
Mendoza, S.M., Konishi, T., Miller, C.W., 1998. Integration of SV40 in
human osteosarcoma DNA. Oncogene 17, 2457–2462.
Monini, M., de Lellis, L., Barbanti-Brodano, G., 1995. Association of BK
and JC human polyomaviruses and SV40 with human tumors. In: Bar-
banti-Brodano, G., Bendinelli, M., Friedman, H. (Eds.), DNA Tumor
Viruses: Oncogenic Mechanisms. Plenum, NY, pp. 51–73.
Mortimer, E.A., Lepow, M.L., Gold, E., Robbins, F.C., Burton, G.J.,
Fraumeni Jr., J.F., 1981. Long-term follow-up of persons inadver-
tently inoculated with SV40 as neonates. N. Engl. J. Med. 305,
1517–1518.
Nickeleit, V., Hirsch, H.H., Binet, I.F., Gudat, F., Prince, O., Dalquen, P.,
Thiel, G., Mihatsch, M.J., 1999. Polyomavirus infection of renal allog-
raft recipients: from latent infection to manifest disease. J. Am. Soc.
Nephrol. 10, 1080–1089.
Nickeleit, V., Hirsch, H.H., Zeiler, M., Gudat, F., Prince, O., Thiel, G.,
Mihatsch, M.J., 2000a. BK-virus nephropathy in renal transplants-tub-
ular necrosis, MHC-class II expression and rejection in a puzzling
game. Nephrol. Dial. Transplant. 15, 324–332.
Nickeleit, V., Klimkait, T., Binet, I.F., Dalquen, P., Del Zenero, V., Thiel,
G., Mihatsch, M.J., Hirsch, H.H., 2000b. Testing for polyomavirus type
BK DNA in plasma to identify renal-allograft recipients with viral
nephropathy. N. Engl. J. Med. 342, 1309–1315.
Nunbhakdi-Craig, V., Craig, L., Machleidt, T., Sontag, E., 2003. Simian
virus 40 small tumor antigen induces deregulation of the actin cytos-
keleton and tight junctions in kidney epithelial cells. J. Virol. 77,
2807–2818.
O’Neill, F.J., Carroll, D., 1981. Amplification of papovavirus defectives
during serial low multiplicity infections. Virology 112, 800–803.
Osborn, M., Weber, K., 1975. Simian virus 40 gene A function and main-
tenance of transformation. J. Virol. 15, 636–644.
Pacini, F., Vivaldi, A., Santoro, M., Fusco, A., Romei, C., Basolo, F.,
Pinchera, A., 1998. Simian virus 40-like DNA sequences in human
papillary thyroid carcinomas. Oncogene 16, 665–669.
Pallas, D.C., Shahrik, L.K., Martin, B.L., Jaspers, S., Miller, T.B., Brauti-
gan, D.L., Roberts, T.M., 1990. Polyoma small and middle T antigens
and SV40 small t antigen form stable complexes with protein phospha-
tase 2A. Cell 60, 167–176.
Palmiter, R., Chen, H., Messing, A., Brinster, R., 1985. SV40 enhancer and
large-T antigen are instrumental in development of choroid plexus tu-
mours in transgenic mice. Nature 316, 457–460.
Pass, H.I., Donington, J.S., Wu, P., Rizzo, P., Nishimura, M., Kennedy, R.,
Carbone, M., 1998. Human mesotheliomas contain the simian virus-40
regulatory region and large tumor antigen DNA sequences. J. Thorac.
Cardiovasc. Surg. 116, 854–859.
Pennisi, E., 1997. Monkey virus DNA found in rare human cancers. Sci-
ence 275, 748–749.
Pepper, C., Jasani, B., Navabi, H., Wynford-Thomas, D., Gibbs, A.R.,
1996. Simian virus 40 large T antigen (SV40LTAg) primer specific
DNA amplification in human pleural mesothelioma tissue. Thorax 51,
1074–1076.
Pipas, J.M., Levine, A.J., 2001. Role of T antigen interactions with p53 in
tumorigenesis. Semin. Cancer Biol. 11, 23–30.
Porcu, P., Ferber, A., Pietrzkowski, Z., Roberts, C.T., Adamo, M., LeRoith,
D., Baserga, R., 1992. The growth-stimulatory effect of simian virus 40
T antigen requires the interaction of insulin-like growth factor 1 with its
receptor. Mol. Cell. Biol. 12, 5069–5077.
Procopio, A., Strizzi, L., Vianale, G., Betta, P., Puntoni, R., Fontana, V.V.,
Tassi, G., Gareri, F., Mutti, L., 2000. Simian virus-40 sequences are a
negative prognostic cofactor in patients with malignant pleural meso-
thelioma. Genes Chromosomes Cancer 29, 173–179.
Randhawa, P.S., Finkelstein, S., Scantlebury, V., Shapiro, R., Vivas, C.,
Jordan, M., Picken, M.M., Demetris, A.J., 1999. Human polyoma virus-
Minireview8associated interstitial nephritis in the allograft kidney. Transplantation
67, 103–109.
Ray, F.A., Peabody, D.S., Cooper, J.L., Cram, L.S., Kraemer, P.M., 1990.
SV40 T antigen alone drives karyotype instability that precedes neo-
plastic transformation of human diploid fibroblasts. J. Cell. Biochem.
42, 13–31.
Reinartz, J.J., 2002. Cancer genes. In: Coleman, W.B., Tsongalis, G.J.
(Eds.), The Molecular Basis of Human Cancer. Humana Press, Totowa,
NJ, pp. 45–64.
Ricciardiello, L., Baglioni, M., Giovannini, C., Pariali, M., Cenacchi, G.,
Ripalti, A., Landini, M.P., Sawa, H., Nagashima, Frisque, R.J., Goel,
A.C., Boland, R., Tognon, M., Roda, E., Bazzoli, F., 2003. Induction of
chromosomal instability in colonic cells by the human polyomavirus JC
through a hit and run mechanism. Cancer Res. (In press).
Rizzo, P., Di Resta, I., Powers, A., Ratner, H., Carbone, M., 1999. Unique
strains of SV40 in commercial poliovaccines from 1955 not readily
identifiable with current testing for SV40 infection. Cancer Res. 59,
6103–6108.
Rizzo, P., Bocchetta, M., Powers, A., Foddis, R., Stekala, E., Pass, H.I.,
Carbone, M., 2001. SV40 and the pathogenesis of mesothelioma.
Semin. Cancer Biol. 11, 63–71.
Rollison, D.E.M., Shah, K.V., 2002. The epidemiology of SV40 infec-
tion due to contaminated polio vaccines: relation of the virus to
human cancer. In: Khalili, K., Stoner, G.L (Eds.), Human Polyoma-
viruses: Molecular and Clinical Perspectives. Wiley-Liss, New York,
pp. 561–584.
Rollison, D.E.M., Helzlsouer, K.J., Alberg, A.J., Hoffman, S., Hou, J.,
Daniel, R., Shah, K.V., Major, E.O., 2003. Serum antibodies to JC
virus, BK virus, simian virus 40, and the risk of incident adult astrocytic
brain tumors. Cancer Epidemiol. Biomark. Prev. 12, 460–463.
Rundell, K., Parakati, R., 2001. The role of the SV40 small t antigen in cell
growth promotion and transformation. Semin. Cancer Biol. 11, 5–13.
Sa´enz-Robles, M.T., Sullivan, C.S., Pipas, J.M., 2001. Transforming func-
tions of Simian Virus 40. Oncogene 20, 7899–7907.
Schlehofer, J.R., zur Hausen, H., 1982. Induction of mutations within the
host cell genome by partially inactivated herpes simplex virus type 1.
Virology 122, 471–475.
Shah, K.V., 1966. Neutralizing antibodies to simian virus 40 (SV40) in
human sera from India. Proc. Soc. Exp. Biol. Med. 121, 303–307.
Shah, K.V., 2000. Does SV40 infection contribute to the development of
human cancers? Rev. Med. Virol. 10, 31–43.
Shah, K.V., Nathanson, N., 1976. Human exposure to SV40. Review and
comment. Am. J. Epidemiol. 103, 1–12.
Shah, K.V., Ozer, H.L., Pond, H.S., Palma, L.D., Murphy, G.D., 1971.
SV40 neutralizing antibodies in sera of US residents without history
of polio immunization. Nature 231, 448–449.
Shein, H.M., Enders, J.F., 1962. Multiplication and cytopathogenicity of
simian vacuolating virus 40 in cultures of human tissues. Proc. Soc.
Exp. Biol. Med. 109, 495–500.
Shimamoto, T., Ohyashiki, K., 2002. Chromosomes and chromosomal
instability in human cancer. In: Coleman, W.B., Tsongalis, G.J.
(Eds.), The Molecular Basis of Human Cancer. Humana Press, Totowa,
NJ, pp. 143–158.
Shivapurkar, N., Harada, K., Reddy, J., Scheuermann, R.H., Xu, Y.,
McKenna, R.W., Milchgrub, S., Kroft, S.H., Feng, Z., Gazdar, A.F.,
2002. Presence of simian virus 40 DNA sequences in human lympho-
mas. Lancet 359, 851–852.
Simmons, D.T., 2000. SV40 large T antigen functions in DNA replication
and transformation. Adv. Virus Res. 55, 75–134.
Stewart, N., Bacchetti, S., 1991. Expression of SV40 large T antigen, but
not small t antigen, is required for the induction of chromosomal aber-
rations in transformed human cells. Virology 180, 49–57.
Stewart, A.R., Lednicky, J.A., Butel, J.S., 1998. Sequence analyses of
human tumor-associated SV40 DNAs and SV40 viral isolates from
monkeys and humans. J. Neurovirol. 4, 182–193.
Stratton, K., Almario, D.A., McCormick, M.C. (Eds.), 2002. Immunization
Safety Review: SV40 Contamination of Polio Vaccine and Cancer. In-stitute of Medicine of the National Academies. The National Academic
Press, Washington, DC. http://www.nap.edu.
Strickler, H.D., Goedert, J.J., 1998. Exposure to SV40-contaminated polio-
virus vaccine and the risk of cancer—A review of the epidemiological
evidence. Dev. Biol. Stand. 94, 235–244.
Strickler, H.D., and The International SV40 Working Group, 2001. A
multicenter evaluation of assays for detection of SV40 DNA and results
in masked mesothelioma specimens. Cancer Epidemiol. Biomark. Prev.
10, 523–532.
Strickler, H.D., Goedert, J.J., Fleming, M., Travis, W.D., Williams, A.E.,
Rabkin, C.S., Daniel, R.W., Shah, K.V., 1996. Simian Virus 40 and
pleural mesothelioma in humans. Cancer Epidemiol. Biomark. 5,
473–475.
Strickler, H.D., Rosenberg, P.S., Devesa, S.S., Hertel, J., Fraumeni, J.F.,
Goedert, J.J., 1998. Contamination of poliovirus vaccines with simian
virus 40 (1955–1963) and subsequent cancer rates. J. Am. Med. Assoc.
279, 292–295.
Suzuki, S.O., Mizoguchi, M., Iwaki, T., 1997. Detection of SV40 T antigen
genome in human gliomas. Brain Tumor Pathol. 14, 125–129.
Sweet, B.H., Hilleman, M.R., 1960. The vacuolating virus SV40. Proc.
Soc. Exp. Biol. Med. 105, 420–427.
Tegtmeyer, P., 1975. Function of simian virus 40 gene A in transforming
infection. J. Virol. 15, 613–618.
Testa, J.R., Carbone, M., Hirvonen, A., Khalili, K., Krynska, B., Linnain-
maa, K., Pooley, F.D., Rizzo, P., Rusch, V., Xiao, G.H., 1998. A multi-
institutional study confirms the presence and expression of simian virus
40 in human malignant mesotheliomas. Cancer Res. 58, 4505–4509.
Tognon, M., Martini, F., Iaccheri, L., Cultrera, R., Contini, C., 2001. In-
vestigation of the simian polyomavirus SV40 as a potential causative
agent of human neurological disorders in AIDS patients. J. Med. Micro-
biol. 50, 165–172.
Van Dyke, T.A., Finlay, C., Miller, D., Marks, J., Lozano, G., Levine,
A.J., 1987. Relationship between simian virus 40 large tumor antigen
expression and tumor formation in transgenic mice. J. Virol. 61,
2029–2032.
Vastag, B., 2002. Sewage yields clues to SV40 transmission. J. Am. Med.
Assoc. 288, 1337–1338.
Vilchez, R.A., Madden, C.R., Kozinetz, C.A., Halvorson, S.J., White, Z.S.,
Jorgensen, J.L., Finch, C.J., Butel, J.S., 2002. Association between
simian virus 40 and non-Hodgkin lymphoma. Lancet 359, 817–823.
Vilchez, R.A., Kozinetz, A., Butel, J.S., 2003. Conventional epidemiol-
ogy and the link between SV40 and human cancers. Lancet Oncol. 4,
188–191.
Viscidi, R.P., Rollison, D.E.M., Viscidi, E., Clayman, B., Rubalcaba, E.,
Daniel, R., Major, E.O., Shah, K.V., 2003. Serological cross-reactivities
between antibodies to simian virus 40, BK virus, and JC virus assessed
by virus-like-particle-based enzyme immunoassays. Clin. Diagn. Lab.
Immunol. 10, 278–285.
Vivaldi, A., Pacini, F., Martini, F., Iaccheri, L., Pezzetti, F., Elisei, R.,
Pinchera, A., Faviana, P., Basolo, F., Tognon, M., 2003. Simian virus
40-like sequences from early and late regions in human thyroid tumors
of different histotypes. J. Clin. Endocrinol. Metab. 88, 892–899.
Volter, C., zur Hausen, H., Alber, D., de Villiers, E.M., 1997. Screening
human tumor samples with a broad-spectrum polymerase chain re-
action method for the detection of polyomaviruses. Virology 237,
389–396.
Waheed, I., Guo, Z.S., Chen, G.A., Weiser, T.S., Nguyen, D.M., Schrump,
D.S., 1999. Antisense to SV40 early gene region induces growth arrest
and apoptosis in T-antigen-positive human pleural mesothelioma cells.
Cancer Res. 59, 6068–6073.
Willert, K., Nusse, R., 1998. h-Catenin: a key mediator of Wnt signaling.
Curr. Opin. Genet. Dev. 8, 95–102.
Woloschak, M., Yu, A., Post, K.D., 1995. Detection of polyomaviral DNA
sequences in normal and adenomatous human pituitary tissues using the
polymerase chain reaction. Cancer 76, 490–496.
Xie, Y.C., Hwang, C., Overwijk, W., Zeng, Z., Eng, M.H., Mule, J.J.,
Imperiale, M.J., Restifo, N.P., Sanda, M.G., 1999. Induction of tumor
Minireview 9antigen-specific immunity in vivo by a novel vaccinia vector encoding
safety-modified simian virus 40 T antigen. J. Natl. Cancer Inst. 91,
169–175.
Yamamoto, H., Nakayama, T., Murakami, H., Hosaka, T., Nakamata, T.,
Tsuboyama, T., Oka, M., Nakamura, T., Toguchida, J., 2000. High
incidence of SV40-like sequences detection in tumour and peripheralblood cells of Japanese osteosarcoma patients. Br. J. Cancer 82,
1677–1681.
Zhao, J.J., Gjoerup, O.V., Subramanian, R.R., Cheng, Y., Chen, W., Rob-
erts, T.M., Hahn, W.C., 2003. Human mammary epithelial cell trans-
formation through the activation of phosphatidylinositol 3-kinase.
Cancer Cell 3, 483–495.
